Dan Benjamin Teleman
Chief Executive Officer at Nasus Pharma Ltd.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 6 months
- Director since
- 2026
6 months of board service in total across 1 board, counting each seat separately. Longest: Nasus Pharma Ltd., 6 months.
Nasus Pharma Ltd.
Director · Chief Executive Officer
Chief executive roles
Nasus Pharma Ltd.
· Chief Executive Officer
2026 – 2026
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | Nasus Pharma Ltd. | Open-market purchase | +6,550 | $3.10 | $20,305 |
| Apr 22, 2026 | Nasus Pharma Ltd. | Open-market purchase | +2,900 | $3.76 | $10,904 |
| Mar 31, 2026 | Nasus Pharma Ltd. | Open-market purchase | +15,000 | $2.04 | $30,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.